Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Inclusion Criteria:

• Women with postmenopausal osteoporosis diagnosed by DXA scanning, defined by T-score of -2.5 SD at spine or femur.
• Patients who have never received bisphosphonates therapy (bisphosphonates naive)

Exclusion Criteria:

• Inability to stand or sit in the upright position for at least 60 minutes;
• Hypersensitivity to any component of risedronate and ibandronate;
• Administration of any investigational drug within 30 days preceding the first dose of the study drug;
• Patient has been on hormone (estrogen) replacement therapy or other osteoporosis medication (e.g. SERMS and calcitonin) within the previous 3 months.
• Patient has been on systemic corticosteroids therapy for more than 1 month within the past year.
• Other bone disease except osteoporosis
• Current medical history of uncontrolled major upper GI disease